CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Fundação Pio XII (FP). Hospital do Câncer de Barretos (Institutional affiliation from the last research proposal) Birthplace: Brazil
graduate at Faculdade de medicina from Universidade Estadual Paulista Júlio de Mesquita Filho (1994). Has experience in Medicine, focusing on Surgical Oncology, acting on the following subjects: sarcomas, melanomas and mesenchymal tumors. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The multidisciplinary auditorium provides essential support for various educational activities, such as classes, seminar presentations, interdisciplinary meetings, and events, including workshops, conferences, and congresses. It is a fundamental resource for the regular activities of our institution's stricto sensu and lato sensu graduate programs. Designed for members of the Pio XII Foun…
The multi-user equipment room at the Molecular Oncology Research Center of Barretos Cancer Hospital, occupies around 36 m2 and houses a technology park for equipment such as flow cytometers, microplate readers, luminometers, ultra and super centrifuges and microscopes. The equipment directly serves users from 16 groups who develop projects in the area of translational oncology. Furthermor…
The multidisciplinary auditorium offers all its users the necessary support to perform multiple didactic activities such as classes, seminar presentations, multidisciplinary meetings, and events as workshops, conferences and lectures. It is an important resource for the regular activities of our stricto sensu and lato sensu graduate programs. Envisioned to cater to Pio XII Foundation memb…
Melanoma accounts for more than 90% of skin cancer deaths. BRAF, NRAS and TERT promoter mutations, together, affect more than two thirds of the melanomas. Screening for BRAF mutations in tumor tissue is important for therapeutic decision and prediction of response to target therapy. Monitoring of metastatic disease using this marker necessitates the availability of tumor sample. Liquid bi…
(Only some records are available in English at this moment)
: Skin cancer is divided into non-melanoma skin cancer and melanoma. Although less frequent, melanoma has higher mortality and poorer prognosis, making early diagnosis crucial for better outcomes. Sentinel lymph node biopsy (SLNB) has been a standard method for staging melanoma for a long time, but it has significant limitations, especially across different age groups. The BAUSSS algorith…
Currently, skin cancer is the most common neoplasm worldwide being commonly divided into melanoma (MSC) and non-melanoma (NMSC). Countries with high ultraviolet (UV) radiation incidence and population with light skin have individuals frequently affected by this neoplasm, with Brazil being an example. Aim: To perform a geographic analysis of skin cancer in municipalities located in the nor…
Melanoma is responsible for a large proportion of deaths associated withskincancer and, despite being frequently associated with the elderly, it is the third most commoncancer in adolescents and young adults. There are risk factors that lead to the development ofthe disease, which is classified into four main subtypes. Pediatric cases are often different frommelanomas in adults and there …
Skin cancer is the most incident cancer of all and is basically divided in non-melanoma and melanoma. Melanoma is the most aggressive type among those described, with a high risk of metastatic dissemination. Its incidence is low in Brazil, but the mortality is considered high. The most frequent clinical sign is the change of a pigment lesion, changing color or its size. Microscopic stagin…
(Only some records are available in English at this moment)
The proposal of the main study is to interrogate the epigenetic role in melanoma initiation and progression. The International Agency for Research on Cancer (IARC) is an intergovernmental agency that is part of the World Health Organization (WHO). Dr Zdenko Herceg is the principal investigator of the Epigenetics Group at IARC. His group has a great expertise in the epigenetic analysis of …
| 1 / 1 | Ongoing grants |
| 7 / 6 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 11 / 9 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 23 / 20 | All research grants and scholarships |
| Associated processes | |